Wellington Management: Atsena Therapeutics: $150 Million (Series C) Closed To Advance Ocular Gene Therapy Programs

Atsena Therapeutics - a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness - recently announced the closing of an oversubscribed $150 million Series C fnuding. The funding was led by Bain Capital's Life Sciences team, with participation from a new investor, Wellington Management. And the company's existing investors also participated in the round, including Lightstone Ventures, Sofinnova Investments, Abingworth, Foundation Fighting Blindness, Hatteras Venture Partners, Osage University Partners, and the Manning Family Foundation. The post Atsena Therapeutics: $150 Million (Series C) Closed To Advance Ocular Gene Therapy Programs appeared first on Pulse 2.0.